BJMO - volume 7, issue 2, may 2013
Tom Feys MBA, MSc
From the 24th till the 26th of January, San Francisco was the setting for the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2013. The meeting, cosponsored by ASCO, ASTRO and SSO, again focused on multidisciplinary approaches to the prevention, screening, evaluation, and management of gastrointestinal (GI) cancers.
(BELG J MED ONCOL 2013;7(2):57–59)
Read moreBJMO - volume 7, issue 2, may 2013
Tom Feys MBA, MSc
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2013 held from the 14th – 16th of February, 2013, in Orlando, Florida, focused on multidisciplinary approaches to the prevention, screening, evaluation, and management of genitourinary (GU) cancers.
(BELG J MED ONCOL 2013;7(2):60–62)
Read moreBJMO - volume 7, issue 1, february 2013
Tom Feys MBA, MSc, J. De Grève MD, PhD
From December 4th-8th 2012, San Antonio, Texas, was again transformed into the world’s capital in the fight against breast cancer. The 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) was a joint presentation of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio, the American Association for Cancer Research, and the Baylor College of Medicine. This years’ meeting drew nearly 8,000 participants from over 90 countries and again proved to be the number one breast cancer meeting in the world. This report does not aim to summarise the entire meeting but discusses the key highlights of the meeting.
(BELG J MED ONCOL 2013;7:31–33)
Read moreBJMO - volume 6, issue 6, december 2012
Tom Feys MBA, MSc
On the 23rd and 24th of November 2012, the Jules Bordet Institute and the Belgian Society of Medical Oncology (BSMO) hosted the 6th Belgian symposium on the integration of molecular biology advances into oncology clinical practice. The aim of this meeting once more was to translate the major advances made in molecular and biological understanding in cancer into clear messages for daily oncological, clinical practice. Over the two days, a plethora of Belgian and international key opinion leaders discussed the clinical impact of molecular advances in several tumour types. Given the high quality of the different lectures, it was not surprising to see that the meeting again obtained the ESMO label. (BELG J MED ONCOL 2012;6:207–211)
Read moreBJMO - volume 6, issue 5, october 2012
Tom Feys MBA, MSc
From September 29th till October 2nd, Vienna formed the spectacular background for the annual meeting of the European Society for Medical Oncology (ESMO). It was the third time that Vienna played host to the ESMO Congress, with previous congresses taking place in 1996 and 2004. However, this years’ edition proved to be the biggest and best congress yet with an astonishing 16,394 delegates from all over the world. Given the vast amount of data presented at ESMO 2012, this report does not aim to summarise the entire meeting, but will focus on ten important take-home messages from the meeting, presented during one of the presidential or proffered paper sessions. All abstracts presented during ESMO 2012 can be consulted at http://abstracts.webges.com/esmo2012/myitinerary. (BELG J MED ONCOL 2012;6:176–180)
Read moreBJMO - volume 6, issue 4, september 2012
Tom Feys MBA, MSc
From April 18th till April 21st, the third European Lung Cancer Conference (ELCC) was hosted in Geneva. Over the past few years, the ELCC has become the reference event in Europe for professionals treating patients with lung cancer. The third edition of this exciting meeting provided a comprehensive multidisciplinary overview of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, early diagnosis, treatment modalities and the result of translational and clinical research. The meeting attracted over 1,500 attendees from all over the world. This report does not pretend to summarise the entire meeting but simply aims at discussing some important take-home messages from the congress. (BELG J MED ONCOL 2012;6:136–139)
Read moreBJMO - volume 6, issue 4, september 2012
J-F. Baurain MD, PhD, W. Lybaert MD
It has become a tradition to hold the biennial International Conference on Thrombosis and Haemostasis Issues in Cancer (ICTHIC) in Bergamo. Bergamo is a quiet town in Northern Italy located on a hilltop beyond the Alps. Over 700 physicians with different backgrounds but the same interest attended the meeting this year from April 20th to April 22nd. The meeting provides a unique opportunity for reviewing the different molecular and clinical findings on thrombosis and haemostasis issues in cancer and for updating the guidelines on prophylaxis and treatment of Venous Thrombo-Embolic Events (VTE) in cancer patients. This congress report covers several key topics: duration of prophylaxis in cancer patients undergoing surgery, prevention in medical cancer patients, type and duration of VTE treatment in cancer patients, place of the newer anti-thrombotic agents in cancer patients and survival advantage of Low-Weight Molecular Heparins (LWMH). (BELG J MED ONCOL 2012;6:140–143)
Read more
Top
